Eli Lilly에 대한 매도 수량은 투자자에게 Eli Lilly의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Eli Lilly (NYSE:LLY) 주식, 공매도 수량 보고

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Health Care

Markets

금요일, 미국 식품의약국(FDA)이 일라이 릴리(NYSE:LLY)의 체중 감량 약물 젭바운드(Zepbound)를 수면 무호흡증 치료제로 승인했다. 무슨 일이 있었나: FDA의 결정으로 젭바운드는 비만과 중증도-심한 폐쇄성 수면 무호흡증(OSA) 환자를 위한 최초의 승인 약물이 되었다.

일라이 릴리의 젭바운드, 비만과 관련된 수면 무호흡증 치료제로 FDA 승인 받아

Exclusives

Trading Ideas

AVGO

NVDA

TSLA

시가총액이 1조 달러를 넘는 기업 목록은 최근 브로드컴(NASDAQ:AVGO)이 분기 재무 결과로 주가가 급등하면서 클럽에 합류한 후 계속해서 증가하고 있다. 벤징가는 독자들에게 다음으로 이 희귀한 클럽에 합류할 회사는 어디일지 물었다.

테슬라와 브로드컴 다음으로 $1조 클럽에 가입할 기업은? 50% 이상이 이 소매업체를 지목

Biotech

Technicals

General

일라이 릴리 앤 컴퍼니(NYSE:LLY)는 150억 달러 규모의 자사주 매입 계획과 15% 배당금 인상으로 화제를 모으고 있다. 그러나 인디애나폴리스에 본사를 둔 이 거대 제약회사는 마운자로(Mounjaro) 및 젭바운드(Zepbound)와 같은 블록버스터 약품의 성공을 누리고 있기 때문에 다음 행보를 앞두고 주가가 엇갈린 기술적 신호를 보내고 있다.

일라이 릴리의 150억 달러 자사주 매입, 차트상 강한 저항선에 직면

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) weight loss drug Zepbound for treating sleep apnea
What Happened: The FDA&#8217;s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA.
&#8220;Too often, OSA is brushed off as &#8216;just snoring,'&#8221; said Julie Flygare, CEO of Project Sleep, in Eli Lilly&#8217;s press release. The condition affects an estimated 80 million Americans, with 20 million experiencing moderate-to-severe forms.
See Also: <a href="https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance">Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo&#8217;s Dominance</a>
In a separate release, the FDA underscored that Zepbound should be used in conjunction with a reduced-calorie diet and increased physical activity for optimal results.
The approval could significantly impact insurance coverage for Zepbound, potentially including Medicare, which currently restricts coverage for obesity drugs unless approved for additional health benefits, <a href="https://www.cnbc.com/2024/12/20/fda-approves-eli-lillys-weight-loss-drug-zepbound-for-sleep-apnea.html">noted</a> CNBC.
This development also gives Eli Lilly an edge over competitor Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), whose Wegovy isn&#8217;t approved for sleep apnea treatment.
Why It Matters: Zepbound's effectiveness was demonstrated in clinical trials. Results showed that nearly half of patients treated with the highest dose experienced disease resolution, the report noted.
This was defined by a significant reduction in their apnea-hypopnea index (AHI), a key metric in diagnosing OSA.
The approval also comes as Eli Lilly continues to <a href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility">expand its manufacturing capabilities</a>, including a $3 billion investment in Kenosha County, Wisconsin in December, to meet the growing demand for its diabetes and obesity medicines.
In October, Eli Lilly reported <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">third-quarter revenue</a> of $11.44 billion, a 20% increase year-over-year, but missed expectations of $12.10 billion. Zepbound generated $1.26 billion.
Price Action: As per <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, LLY shares increased by 1.35% to $767.76 on Friday. So far this year, LLY has risen by 29.65%.
The latest ratings from B of A Securities, Wolfe Research, and Deutsche Bank set an average price target of $1,004, indicating a potential upside of 30.77%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/LLY/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/21033911/Screenshot-2024-12-21-at-2.09.01%E2%80%AFPM-1024x374.png" alt="" class="wp-image-702686" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41318886/eli-lillys-alzheimers-drug-raises-hopes-but-faces-regulatory-hurdles-in-europe">Eli Lilly&#8217;s Alzheimer&#8217;s Drug Raises Hopes but Faces Regulatory Hurdles in Europe</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug

FDA Approves Eli Lilly's Zepbound For Moderate-to-Severe Obstructive Sleep Apnea In Adults With Obesity

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped <a href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges">obesity drug, CagriSema. </a>
To put the move in perspective, the only steeper plunge in the Danish pharma giant's history was a 26.2% collapse during the infamous Black Monday crash of October 1987.
Once the poster child of the obesity drug boom, Novo failed to meet the market's sky-high expectations, sparking a $20 billion wipe out in market value.
Here's what happened—and why some analysts believe Wall Street might have overreacted.
<h3 class="wp-block-heading">Trial Results Fall Short of High Expectations</h3>
CagriSema, a combination of cagrilintide and semaglutide, is part of Novo Nordisk's REDEFINE clinical program, designed to compete in the lucrative obesity drug market. 
The REDEFINE 1 Phase 3 trial, which involved 3,417 participants with obesity or overweight conditions, demonstrated a 22.7% weight loss after 68 weeks for patients taking CagriSema. 
While impressive compared to the 2.3% weight loss with placebo, the result was slightly below Novo's previously teased goal of a 25% reduction.
By comparison:
<ul>
<li>CagriSema: 22.7% weight loss</li>
<li>Semaglutide alone: 16.1% weight loss</li>
<li>Cagrilintide alone: 11.8% weight loss</li>
<li>Placebo: 2.3% weight loss</li>
</ul>
Additionally, 40.4% of patients taking CagriSema lost at least 25% of their body weight, compared to just 16.2% with semaglutide and a negligible 0.9% with placebo.
While the trial data were statistically significant, they fell shy of the hype surrounding Novo's claims that CagriSema could deliver 25% weight loss without added side effects.
<h3 class="wp-block-heading">Analysts Call The Selloff &#8216;Overdone&#8217;</h3>
Despite the sharp decline, several industry insiders believe the market overreacted. 
Maurits Pot, founder of Tema ETFs, which manages the GLP-1 Obesity &amp; Cardiometabolic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>), told Benzinga: "This is the latest major event in the obesity space in what has proven to be a very volatile second half of the year.&#8221;
Tema ETFs had already been underweight Novo, holding just a 3.99% stake prior to the REDEFINE 1 results. 
Pot has been for long championing the case that the weight-loss market is far from being dominated by a duopoly – Novo Nordisk and Ely Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
&#8220;This latest readout from Novo today underscores why only betting on NOVO and LLY in the GLP-1 is very risky and has not worked in the second half of 2024,&#8221; he stated.
Despite this, he described Novo Nordisk&#8217;s sharp selloff as an &#8220;overreaction&#8221; and told Benzinga that the HRTS fund is taking advantage of Friday&#8217;s dip to add more shares.
Goldman Sachs analyst James Quigley offered a similar perspective in a note released Friday.
"While these weight loss data are lower than hoped in the market, we still believe that the product [CagriSema] will be filed and approved by the FDA,&#8221; Quigley stated.
The expert sees Novo's market position moving &#8220;from one where they had a clearly inferior product in Wegovy to one that is on par with Zepbound in terms of weight loss.&#8221;
&#8220;We see the share price move as overdone and with CagriSema offering another high efficacy option, it could still protect part of the longer term obesity franchise,&#8221; he added. 
Goldman maintained a bullish stance on Novo Nordisk, setting a 12-month price target of $148 for the ADR—a potential 75% upside from Friday's market price.
NVO Price Action: Shares of Novo Nordisk were down 18.5% to $84.25 at the time of publication Friday.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Regulations

Sector ETFs

Eurozone

Movers

ETFs

HRTS

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss

Macro Economic Events

Market Summary

Economics

Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher

WIIM

Lilly shares are trading higher in reaction to weight loss data from competitor Novo Nordisk.

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082" target="_blank" rel="noreferrer noopener">global REDEFINE program</a>.
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo, all administered once-weekly.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42467660/novo-nordisks-ozempic-label-expansion-snags-approval-from-european-drug-regulators-advisory-panel" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Label Expansion Snags Approval From European Drug Regulator&#8217;s Advisory Panel</a>
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082" rel="noreferrer noopener">trial</a> included 3,417 randomized people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss with CagriSema versus placebo at week 68.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.
When applying the treatment policy estimand, people treated with CagriSema achieved a weight loss of 20.4% compared to a reduction of 11.5% with cagrilintide 2.4 mg, 14.9% with semaglutide 2.4 mg and 3.0% with placebo.
In the trial, CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.
The results from the second pivotal phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight are expected during the first half of 2025.
In reaction to lower-than-expected trial data, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading higher. Lilly&#8217;s own obesity injection containing tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment <a target="_blank" href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years" rel="noreferrer noopener">period for the efficacy estimandi</a>.&nbsp;
Recently, Novo Nordisk stock came under pressure when two new studies from the University of Southern Denmark suggested that Ozempic, a diabetes medication, may increase the risk of developing a <a target="_blank" href="https://www.benzinga.com/24/12/42557565/ozempic-maker-novo-nordisks-poised-to-go-under-european-review-for-potential-increased-risk-of-rare-eye-disease" rel="noreferrer noopener">rare eye condition</a>.
Price Action: NVO stock is down 16.50% at $86.33, and LLY stock is up 8.91% at $825 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" target="_blank" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a></li>
</ul>
Photo via Shutterstock

Large Cap

Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

<a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" title="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize</a>

Hims & Hers Health, Inc. Class A Common Stock

HIMS

FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection

The list of companies that have market capitalizations greater than $1 trillion continues to grow with Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) recently joining the club after its quarterly financial results sparked <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488220/broadcom-hits-1-trillion-milestone-the-next-magnificent-tech-giant">a rally in shares.</a>
A Benzinga poll asks readers which company could be next to join the elusive club.
What Happened: Less than two years ago, investors could count on one hand the number of companies that were valued at more than $1 trillion. That changed in May 2023 when NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) became the sixth company in the club and ninth public company in history to be valued at <a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club">more than $1 trillion.</a>
Fast forward to December 2024 and there are now 10 companies valued at $1 trillion or more. Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) crossed the milestone earlier this year and currently hovers near it again, with a market capitalization of $983 billion.
Here is the current list of members in the $1 trillion market capitalization club, according to <a href="https://companiesmarketcap.com/">Companiesmarketcap.com</a>:
<ul>
<li>Apple: $3.82 trillion</li>
<li>Microsoft: $3.35 trillion</li>
<li>Nvidia: $3.30 trillion</li>
<li>Amazon.com: $2.43 trillion</li>
<li>Alphabet: $2.39 trillion</li>
<li>Saudi Aramco: $1.83 trillion</li>
<li>Meta Platforms: $1.57 trillion</li>
<li>Tesla: $1.52 trillion</li>
<li>Broadcom: $1.10 trillion</li>
<li>Taiwan Semiconductor: $1.06 trillion</li>
</ul>
Benzinga recently asked who will be the next company to join the club for the first time with Berkshire Hathaway left out due to its close proximity and the fact it had already been in the club.
"Following Broadcom, which company will join the $1 trillion club next?" Benzinga asked.
The results were as follows along with the market caps at the time the poll was conducted:
<ul>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), $759 billion: 53%</li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), $757 billion: 24%</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), $675 billion: 13%</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), $619 billion: 9%</li>
</ul>
Over half of readers polled said they believe Walmart will be the next company to join the $1 trillion club for the first time, followed by Eli Lilly at around one fourth of readers.
Here's a look at the current year-to-date and five-year returns of the four stocks featured in the poll:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="765" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18143238/output-1024x765.png" alt="" class="wp-image-698436" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18143238/output-1024x765.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18143238/output-300x224.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18143238/output-768x574.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18143238/output.png 1446w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Chart created using ChatGPT.
The chart above shows that while Walmart is the top gainer year-to-date, it is Eli Lilly that has the better five-year stock growth.
Read Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/07/39618512/nancy-pelosi-loads-up-on-more-nvidia-shares-sells-tesla-she-always-reports-right-before-a-hol">Nancy Pelosi Loads Up On More Nvidia Shares, Buys Broadcom Options </a>
Why It's Important: Broadcom stock is up 28% over the last five days and up over 113% year-to-date. The company <a href="https://www.benzinga.com/news/earnings/24/12/42472970/broadcom-reports-mixed-q4-results-eps-beat-revenues-miss-q1-guidance-in-line-with-estimates">beat fourth-quarter</a> analyst earnings per share, missed revenue estimates and provided guidance that was in-line. The guidance and positive outlook was enough to send shares higher and provide entry into the club.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), which was previously a member of the club, has <a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion">rejoined the $1 trillion club</a> thanks to impressive gains for the electric vehicle stock since Donald Trump won the 2024 presidential election.
Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is another company that was previously in the $1 trillion club years ago and rejoined the club earlier this year.
In August, <a href="https://www.benzinga.com/top-stories/24/08/40604676/warren-buffetts-berkshire-hathaway-breaks-1-trillion-poll-points-to-big-pharma-not-tech-as-next-cont">Benzinga polled readers </a>to ask which company they thought would hit the $1 trillion valuation next after Berkshire Hathaway joined.
The results were:
<ul>
<li>Eli Lilly: 43%</li>
<li>Taiwan Semiconductor: 25%</li>
<li>Tesla: 19%</li>
<li>Broadcom: 11%</li>
<li>Walmart: 3%</li>
</ul>
That poll was conducted when Eli Lilly and Taiwan Semiconductor both traded with market capitalizations of around $800 billion. Readers ended up being wrong with Eli Lilly still out of the club, while Taiwan Semiconductor, Tesla and Broadcom have all joined in recent months.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42121665/could-another-magnificent-7-stock-beat-nvidia-in-2025-poll-says-not-likely-27-pick-this-potential-winner">Could Another Magnificent 7 Stock Beat Nvidia In 2025? Poll Says Not Likely, 27% Pick This Potential Winner</a></li>
</ul>
The study was conducted by Benzinga from Dec. 16 through Dec. 17, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 128 adults.
Image created using artificial intelligence via Midjourney.

Who's Next To Join Tesla, Broadcom In $1 Trillion Club? Over 50% Say The World's Biggest Retailer

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRDF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$56.3K</td>
<td>1.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$500.00</td>
<td>$51.9K</td>
<td>2.4K</td>
<td>687</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.00</td>
<td>$34.4K</td>
<td>2.0K</td>
<td>648</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$37.00</td>
<td>$47.5K</td>
<td>1.8K</td>
<td>321</td>
</tr>
<tr>
<td>PEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$280.00</td>
<td>$52.2K</td>
<td>0</td>
<td>223</td>
</tr>
<tr>
<td>NMRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$36.0K</td>
<td>13.7K</td>
<td>104</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$90.00</td>
<td>$25.0K</td>
<td>3.6K</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$97.00</td>
<td>$25.8K</td>
<td>28</td>
<td>46</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$290.00</td>
<td>$29.8K</td>
<td>26</td>
<td>42</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$780.00</td>
<td>$127.8K</td>
<td>238</td>
<td>27</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CRDF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>), we observe a call option sweep with bullish sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 663 contract(s) at a $5.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $56.3K, with a price of $88.0 per contract. There were 1040 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option sweep that happens to be neutral, expiring in 30 day(s) on January 17, 2025. This event was a transfer of 21 contract(s) at a $500.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $51.9K, with a price of $2480.0 per contract. There were 2415 open contracts at this strike prior to today, and today 687 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on December 20, 2024. This event was a transfer of 128 contract(s) at a $32.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $34.4K, with a price of $279.0 per contract. There were 2000 open contracts at this strike prior to today, and today 648 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option sweep with bullish sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $37.00 strike. This particular put needed to be split into 41 different trades to become filled. The total cost received by the writing party (or parties) was $47.5K, with a price of $190.0 per contract. There were 1897 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• For PEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), we notice a call option trade that happens to be bullish, expiring in 212 day(s) on July 18, 2025. This event was a transfer of 25 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $52.2K, with a price of $2090.0 per contract. There were 0 open contracts at this strike prior to today, and today 223 contract(s) were bought and sold. 
• Regarding NMRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>), we observe a call option trade with neutral sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $360.0 per contract. There were 13769 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option trade with bullish sentiment. It expires in 394 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 3611 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bearish sentiment. It expires in 2 day(s) on December 20, 2024. Parties traded 22 contract(s) at a $97.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $1175.0 per contract. There were 28 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option sweep that happens to be neutral, expiring in 120 day(s) on April 17, 2025. This event was a transfer of 15 contract(s) at a $290.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $29.8K, with a price of $1990.0 per contract. There were 26 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be neutral, expiring in 184 day(s) on June 20, 2025. This event was a transfer of 18 contract(s) at a $780.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $127.8K, with a price of $7105.0 per contract. There were 238 open contracts at this strike prior to today, and today 27 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

CRDF

NMRA

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

FDA Clears Gan & Lee's Investigational New Drug Application To Conduct Phase 2 Head-To-Head Trial Of Bi-Weekly Bofanglutide, For Chronic Weight Management Indication Against Eli Lilly's Tirzepatide

<ul>
<li>China is the fourth major market where Kisunla has received approval&nbsp;</li>
<li>Kisunla was first approved in&nbsp;the United States&nbsp;in&nbsp;July 2024, approved in&nbsp;Japan&nbsp;in&nbsp;September 2024 and then in Great Britain in October 2024</li>
</ul>

Reported Earlier, China Approves Eli Lilly's Kisunla For Early Symptomatic Alzheimer's Disease, Following U.S., Japan, And Great Britain

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has fallen 10.39% since its last report. The company recently reported that it has 5.84 million shares sold short, which is 0.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734467410_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Eli Lilly's Recent Short Interest

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 37%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $857,114, and 11 are calls, for a total amount of $676,636.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $430.0 to $900.0 for Eli Lilly over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 234.0, with a total volume reaching 262.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $430.0 to $900.0, throughout the last 30 days.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734447650_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$61.0</td>
<td>$56.5</td>
<td>$61.0</td>
<td>$710.00</td>
<td>$286.7K</td>
<td align="right">95</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$56.9</td>
<td>$53.3</td>
<td>$56.9</td>
<td>$700.00</td>
<td>$221.9K</td>
<td align="right">448</td>
<td align="right">39</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$41.8</td>
<td>$38.6</td>
<td>$41.8</td>
<td>$710.00</td>
<td>$167.2K</td>
<td align="right">53</td>
<td align="right">40</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$28.5</td>
<td>$27.85</td>
<td>$28.5</td>
<td>$720.00</td>
<td>$125.4K</td>
<td align="right">298</td>
<td align="right">98</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$232.0</td>
<td>$223.55</td>
<td>$227.0</td>
<td>$660.00</td>
<td>$113.5K</td>
<td align="right">18</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>Trading volume stands at 389,869, with LLY's price up by 0.04%, positioned at $779.29.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 49 days.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $997.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from B of A Securities lowers its rating to Buy with a new price target of $997.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Eli Lilly's Latest Options Trends

<ul>
<li>Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.&nbsp;</li>
<li>This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030</li>
</ul>

The Egyptian Drug Authority Approved The Insulin Glargine Injection Manufactured By EVA Pharma Through A Collaboration With Eli Lilly

<a href="https://www.youtube.com/watch?v=fjFI9jPVh-A" title="https://www.youtube.com/watch?v=fjFI9jPVh-A">https://www.youtube.com/watch?v=fjFI9jPVh-A</a>

Global

President-Elect Donald J. Trump Says 'We're Going To Knock Out The Middlemen' Who Are Keeping Drug Prices High

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) today jointly announced a Distribution and Promotion Agreement in Mainland China regarding Lilly's non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca&#xAE; (pirtobrutinib, 100 mg &amp; 50 mg tablets). The agreement highlights the following aspects:
<ul>
<li>Innovent will be responsible for the importation, marketing, distribution and promotion of Jaypirca&#xAE;;</li>
<li>Lilly will be responsible for the R&amp;D and post-market medical affairs of&nbsp;Jaypirca&#xAE;.</li>
</ul>

IVBIY

Reported Earlier, Innovent And Lilly Expand Global Oncology Partnership Through Jaypirca Commercialization Deal In China

<a href="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic" title="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic">https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic</a>

AMGN

DRIO

LFVN

TERN

VANI

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion&nbsp;
VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat symptom of bowel urgency using a patient-centric scale
Omvoh will be the first treatment for Crohn's disease with results demonstrating improvements of histologic measures of inflammation included in its label, if approved by the European Commission
Lilly has also submitted Omvoh in the U.S. for approval to treat adults with moderately to severely active Crohn's disease, with a decision expected in the first half of 2025
INDIANAPOLIS, Dec. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh&#xAE; (mirikizumab), an interleukin-23p19 (IL-23p19) antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Eli Lilly Announces Omvoh Has Been Recommended By EMA's CHMP For Approval In The European Union For Adults With Moderately To Severely Active Crohn's Disease; The Phase 3 VIVID-1 Trial Evaluated The Safety And Efficacy Of Omvoh In Patients With Or Without Prior Biologic Failure And Was The Basis For The Positive Opinion

Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has achieved a year-to-date (YTD) increase of&nbsp;32.11% as of Friday, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. This&nbsp;surge has had varied effects on several ETFs that hold significant stakes in the pharmaceutical giant. Several ETFs with substantial holdings in Eli Lilly have experienced varied performances during the same period.
What Happened:&nbsp;The&nbsp;iShares U.S. Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) with a 20.33% allocation to Eli Lilly, reported a YTD gain of 10.89%. Meanwhile, the&nbsp;Roundhill GLP-1 &amp; Weight Loss ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZEM#NASDAQ">OZEM</a>), holding 15.86% in Eli Lilly, saw a modest YTD increase of 3.74%.
See Also:&nbsp;<a href="https://www.benzinga.com/24/12/42438029/candel-therapeutics-prostate-cancer-therapy-hits-primary-goal-in-late-stage-study-stock-surges-over-100?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Candel Therapeutics Stock Surges Over 100%</a>
Conversely, the&nbsp;Horizon Kinetics Medical ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDX#NASDAQ">MEDX</a>), with Eli Lilly making up 16.06% of its portfolio, experienced a YTD decline of 1.56%. Similarly, the&nbsp;Amplify Weight Loss Drug &amp; Treatment ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THNR#NYSE">THNR</a>), with a 14.43% exposure to Eli Lilly, also saw its YTD returns decrease by 6.27%.
Lastly, the iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which includes an 11.76% stake in Eli Lilly, recorded a YTD increase of 2.68%.
Buying $1000 In LLY vs. ETFs: If an investor had bought $1000 of LLY stock earlier this year, it would be worth $1,251 today based on a price of $782.35 for Eli Lilly at the time of writing. At the same time, IHE would have been worth $1100 based on a price of $67.11 for iShares US Pharmaceuticals ETF at the time of writing.
Why It Matters: Recently, the company announced a&nbsp;<a href="https://www.benzinga.com/general/biotech/24/12/42421676/eli-lilly-15b-buyback-faces-stiff-resistance-on-the-charts">massive $15 billion share buyback plan</a>&nbsp;and a 15% dividend increase. These strategic moves come as the company enjoys the success of its blockbuster drugs, Mounjaro and Zepbound, despite facing mixed technical signals on the charts.
Moreover,&nbsp;Eli Lilly&nbsp;has been heavily investing in its production capabilities. The company recently announced a&nbsp;<a href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility">$3 billion expansion</a>&nbsp;of its manufacturing facility in Kenosha County, Wisconsin. This expansion is part of a broader $23 billion investment to meet the growing demand for diabetes, obesity, and pipeline medicines, further solidifying its position in the pharmaceutical industry.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42462096/keros-therapeutics-pauses-two-treatment-arms-in-mid-stage-hypertension-trial-stock-plummets?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Keros Therapeutics Loses 75% Value In A Single Session</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

MEDX

OZEM

Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF

THNR

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares

BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema's ...

BMO lowers Novo Nordisk price target to $105, says reaction to data 'overdone'

Biggest stock movers Friday: RGTI, CCL, NVO, DXCM and more

Pfizer gets FDA accelerated approval for Braftovi

Eli Lilly (LLY) announced the FDA approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe obstructive slee...

Eli Lilly announces FDA approval for Zepbound

Eli Lilly's Zepbound gains sleep apnea indication

Eli Lilly announces FDA approval for Zepbound for obstructive sleep apnea

If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy

Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup

Trending stocks in bearish pre-holiday week for U.S. stock market

Materials, software stocks are best poised for H1 outperformance: Goldman Sachs

AAPL

ABBV

AKAM

ARQQ

BIIB

BKNG

CBRE

COST

CRWD

CTSH

DXCM

EPAM

EQIX

EVRG

FICO

GOOG

GOOGL

INCY

IONQ

LCID

MSFT

PLTR

PODD

QBTS

QUBT

RGTI

SOUN

TEVA

TMUS

TNDM

VICI

VRTX

VTRS

WELL

XLRE

XMTR

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Contracts

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Opinion

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

Comments

Eli Lilly

매도 수량

Eli Lilly (NYSE:LLY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌